Table 4 Effect of sympatho-inhibition (moxonidine 0.4 mg) on 24-h SBP
From: Identifying treatment response to antihypertensives in patients with obesity-related hypertension
24 h SBP | P for interaction | ||
|---|---|---|---|
Sex | Men | −3 (−8 to 3) | 0.06 |
Women | −4 (−7 to −1) | ||
Age | > 60 years | −2 (−7 to 3) | 0.09 |
≤ 60 years | −4 (−9 to 1) | ||
BMI | > 30.7 kg/m2 | −4 (−11 to 3) | 0.91 |
≤ 30.7 kg/m2 | −3 (−8 to 2) | ||
Waist (sexpooled) | Men > 111 cm Women >98 cm | −2 (−10 to 7) | 0.84 |
Men ≤ 111 cm Women ≤ 98 cm | −4 (−9 to 1) | ||
Heart rateb | > 71/min | −8 (−15 to - 2) | 0.53 |
≤ 71/min | −1 (−5 to 4) | ||
MSNA | > 46 bpm | 0 (−9 to 9) | 0.15 |
≤ 46 bpm | −7 (−14 to 0) | ||
hs-CRPc | > 1.8 mg/L | −5 (−10 to 1) | 0.46 |
≤ 1.8 mg/L | −2 (−7 to 3) | ||
Renin | > 57.2 pg/ml | −2 (−9 to 5) | 0.07 |
≤ 57.2 pg/ml | −5 (−11 to 0) | ||
Aldosterone | > 53.4 pg/ml | −4 (−12 to 3) | 0.84 |
≤ 53.4 pg/ml | −4 (−9 to 1) | ||
Sodium intakea | > 87 mmol/day | −4 (−11 to 4) | 0.25 |
≤ 87 mmol/day | −4 (−9 to 1) | ||
Glucose | > 5.1 mmol/L | −5 (−12 to 2) | 0.81 |
≤ 5.1 mmol/L | −3 (−8 to 2) | ||
Adiponectinc | > 68.9 μg/ml | −5 (−10 to 1) | 0.31 |
≤ 68.9 μg/ml | −4 (−11 to 3) | ||
Leptinc | > 16.4 ng/ml | −6 (−11 to 1) | 0.45 |
≤ 16.4 ng/ml | −2 (−8 to 4) |